Loading clinical trials...
Loading clinical trials...
VP-VLY-686-3301: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Iii Study To Assess The Efficacy Of Tradipitant In Relieving Symptoms Of Gastroparesis
To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
Vanda Investigational Site
Birmingham, Alabama, United States
Vanda Investigational Site
Peoria, Arizona, United States
Vanda Investigational Site
Little Rock, Arkansas, United States
Vanda Investigational Site
Chula Vista, California, United States
Vanda Investigational Site
La Jolla, California, United States
Vanda Investigational Site
Los Angeles, California, United States
Vanda Investigational Site
Los Angeles, California, United States
Vanda Investigational Site
Maitland, Florida, United States
Vanda Investigational Site
Palmetto Bay, Florida, United States
Vanda Investigational Site
Tampa, Florida, United States
Start Date
August 20, 2019
Primary Completion Date
February 21, 2025
Completion Date
February 21, 2025
Last Updated
July 24, 2025
992
ACTUAL participants
Tradipitant
DRUG
Placebo
DRUG
Open Label Tradipitant
DRUG
Lead Sponsor
Vanda Pharmaceuticals
NCT03876288
NCT06803589
NCT06046833
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions